Pure Insulin Nanoparticle Agglomerates for Pulmonary Delivery

Diabetes is a disease characterized by defects in insulin utilization, either through autoimmune destruction of insulin-producing cells (Type I) or insulin resistance (Type II). Treatment includes regular insulin injections, which can be painful and inconvenient, often leading to low patient compliance. To overcome this problem, novel formulations of insulin are being investigated, such as inhaled aerosols. Sufficient deposition of powder in the distal regions of the lung to maximize systemic absorption requires precise control over particle size, with particles between 1 and 5 microns in aerodynamic diameter being within the respirable range. Insulin nanoparticles were produced by titrating insulin dissolved at low pH to the pI of the native protein, and were then processed into microparticles using solvent displacement. Particle size, crystallinity, dissolution properties, stability, and powder density were characterized. This work demonstrates that pure insulin microparticles can be produced from nanosuspensions with minimal processing steps and with suitable properties for deposition in the peripheral lung.

Grantor dc:publisher

University of Kansas

Year dc:date.issued

2008

Author dc:creator

• Bailey, Mark Michael

Advisor dc:contributor.advisor

• Berkland, Cory J

• Chemical engineering
• Pharmaceutical chemistry
• Biomedical engineering
• Insulin
• Pulmonary delivery
• Nanotechnology
• Drug delivery

Statement dc:rights

• This item is protected by copyright and unless otherwise specified the copyright of this thesis/dissertation is held by the author.

Language dc:language.iso

EN

Dc Identifier Other

http://dissertations.umi.com/ku:2440

OAI identifier oai:identifier

oai:kuscholarworks.ku.edu:1808/3945